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Changes in initial COPD treatment choice over time and
factors inﬂuencing prescribing decisions in UK primary care:
in UK primary care: a real-world, retrospective, observational
Kevin Gruffydd-Jones1, Guy Brusselle2,3, Rupert Jones4, Marc Miravitlles5, Michael Baldwin6, Rebecca Stewart7, Anna Rigazio7,
Emily Davis7, Dorothy L Keininger8 and David Price7,9
Prescribing patterns in chronic obstructive pulmonary disease (COPD) are often inconsistent with published guidelines. This
retrospective, observational study utilised data from the Optimum Patient Care Research Database to examine the changes in
COPD prescribing patterns over time and to identify predictors of physician treatment choice for patients newly diagnosed with
COPD. Initial therapy was deﬁned as the treatment(s) prescribed at or within 1 year before COPD diagnosis. Changes over time were
assessed in three cohorts based on the date of diagnosis: (1) 1997–2001; (2) 2002–2006; and (3) 2007–2010. Factors affecting the
odds of being prescribed any initial therapy or any initial maintenance therapy were identiﬁed by univariable and multivariable
logistic regression. The analysis included 20,154 patients, 45% of whom were prescribed an initial regimen containing an inhaled
corticosteroid (ICS), whereas 28% received no initial pharmacological treatment. Prescribing of ICS monotherapy decreased over
time, as did the proportion of patients receiving no therapy at or within 1 year before diagnosis. Comorbid asthma, a high
exacerbation rate, increased symptoms and poor lung function each increased the likelihood of being prescribed any initial therapy
or initial maintenance therapy; comorbid asthma and an annual rate of ⩾ 3 exacerbations were the strongest predictors.
In conclusion, our analyses revealed major differences between actual prescribing behaviour and guideline recommendations
for patients with newly diagnosed COPD, with many patients receiving no treatment and large numbers of patients receiving
ICS-containing regimens. Predictors of initial therapy were identiﬁed.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) places a high
burden on the healthcare system and society in the UK.1 An
effective way to minimise the burden of any disease is through
appropriate care, including pharmacological management. In the
UK, most COPD care is provided in primary care.2 However,
recommendations in national and international guidelines are
based on evidence obtained in randomised clinical trials,3 which
recruit patients mainly from secondary or tertiary care. Patients
enrolled into randomised clinical trials differ from those seen in
primary care in that they may be younger, take fewer concomitant
medications and have more severe airﬂow limitation, worse
quality of life, fewer comorbidities, a more signiﬁcant smoking
history and a clearer diagnosis of COPD.4–7 Thus, although primary
care treatment decisions should be based on the guidelines,
adaptation of management strategies to reﬂect the characteristics
of patients seen in primary care is warranted.3
The UK National Institute for Health and Care Excellence (NICE)
guidelines for COPD were introduced in 2004 and updated
partially in 2010.8,9 They recommend a multidimensional
approach to the assessment of COPD severity, taking into account
the degree of airﬂow obstruction and factors such as disability and
exacerbation frequency.8–10 In the 2004 guidelines, therapy
recommendations focused on treating symptoms, with short-
and long-acting bronchodilators recommended for symptomatic
patients, and inhaled corticosteroid (ICS) reserved only for
frequent exacerbators with a forced expiratory volume (FEV1)
⩽ 50% predicted.8 In the updated (2010) guidelines, the treatment
focus shifted to the prevention of future risk, with treatment
choice being determined by the level of post-bronchodilator
FEV1.
9,10
In contrast to the 2004 NICE guidelines, the 2003 Global
initiative for chronic Obstructive Lung Disease (GOLD) recom-
mendations assessed disease severity solely on the basis of airﬂow
limitation.11 They recommended the initial use of bronchodilators
to treat symptoms and ICS as an add-on therapy in patients with
FEV1o50% predicted and frequent exacerbations (e.g., three in
the last 3 years). The updated GOLD strategy recommends that
COPD is assessed according to current symptoms and future risk,
based on lung function and exacerbation frequency.12 Currently,
the use of ICS (in combination with bronchodilators) is
recommended only for patients at high risk of exacerbations
(⩾2 exacerbations per year, or ⩾1 leading to hospital admission).12
Prescribing patterns for COPD are often not in accordance with
guidelines. Previous studies, including one from our group,13 have
shown a higher use of ICS and under-prescription of
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bronchodilators than expected based on the guidelines. Many
patients do not receive any treatment despite experiencing
symptoms, whereas others receive treatment without due regard
to severity of airﬂow limitation, asthma diagnosis or exacerbation
history, and without appropriate spirometric assessment.13–21
These ﬁndings highlight some important issues regarding the
treatment of patients in primary care. To understand why these
prescribing patterns occur, an assessment of the predictors of
physician prescribing behaviour, an area currently unexplored in
the literature, is required.
The aims of this retrospective, observational study were to
examine the changes in COPD prescribing patterns over time and
to identify predictors of physician treatment choice for patients
newly diagnosed with COPD.
RESULTS
Patients
Of 42,704 patients registered in the study period, 20,154 met
the eligibility criteria and were included in the analysis
(Supplementary Figure S1). The median age of patients across
all cohorts was 66 years (Table 1). The proportions of men and
women were similar (52 and 48%, respectively). The majority of
patients were ex-smokers (49%) or current smokers (46%); 4.4% of
patients were classiﬁed as non-smokers, and there were also
three patients with unknown smoking status. Patient baseline
characteristics per cohort are presented in Supplementary
Table S1; the prevalence of speciﬁc comorbidities in the overall
study population is shown in Supplementary Table S2.
COPD initial treatment patterns
Analysis of initial therapy in the overall study population showed
that 45% of patients were prescribed ICS, either alone or in
combination with a long-acting β2-agonist (LABA) and/or long-
acting muscarinic antagonist (LAMA); Figure 1. More than one in
four patients (28%) did not receive any prescription.
Analysis of initial therapy according to year of COPD diagnosis
showed that ICS monotherapy prescriptions decreased from the
1997–2001 cohort to the 2002–2006 and 2007–2010 cohorts,
whereas ICS/LABA prescriptions and triple therapy (ICS/LABA/
LAMA) increased progressively over time (Figure 2). There were no
prescriptions for LAMAs in the 1997–2001 cohort, because LAMA
therapy was not available in the UK until 2002.22 The proportion of
patients receiving no therapy at or within 1 year before COPD
diagnosis decreased progressively over time, from 33 to 26%
(Figure 2).
Predictors of initial COPD treatment
Results from the univariable analysis to identify factors predicting
any initial therapy and initial maintenance therapy are presented
in Supplementary Table S3. Multivariable analysis of patients
receiving their ﬁrst therapy during the year before or at the date
of COPD diagnosis (subset of patients with modiﬁed Medical
Research Council (mMRC) data available (n = 16,185)) showed that
patients with an annual rate of ⩾ 3 exacerbations had 4.6 times
higher odds of receiving any initial COPD therapy and 3.8 times
higher odds of receiving initial maintenance therapy than patients
with no exacerbations. Patients with comorbid asthma had 3.9
and 5.5 times higher odds of receiving any/initial maintenance
therapy, respectively, than patients without comorbid asthma.
Lung function grade and mMRC score were weaker predictors of
therapy choice (Tables 2 and 3).
In an analysis of the subgroup of patients who received their
ﬁrst therapy on the date of COPD diagnosis, mMRC score or an
annual exacerbation rate of ⩾ 3 (versus 0) were not found to be
predictors of any/initial maintenance therapy. Having a lung
function Grade of 3 or 4 (versus Grade 2) did not signiﬁcantly
affect the odds of receiving initial therapy, but patients with lung
function Grade 3 or 4 were more likely to receive initial
maintenance therapy than patients with lung function Grade 2
(odds ratio 1.2 and 1.6, respectively). Patients with comorbid
asthma were less likely to be prescribed initial therapy than
patients without comorbid asthma (odds ratio 0.8); comorbid
asthma was not a predictor of maintenance treatment in this
patient subgroup (Tables 2 and 3).
DISCUSSION
Main ﬁndings
Our analyses showed that 28% of patients did not receive any
pharmacological therapy at or within 1 year before COPD
diagnosis, which is surprising given the high levels of symptoms
and poor lung function in our study population. However,
the proportion of patients receiving no therapy decreased over
time, perhaps because of increased awareness among physicians
(e.g., with the introduction of the Quality and Outcomes
Framework (QOF) in the UK in 2004,23 and GOLD and NICE
treatment guidelines/recommendations in 200124 and 2004,8
respectively) and improved data recording.25 In the total study
population, a diagnosis of comorbid asthma and a higher rate of
exacerbations were strongly predictive of an increased likelihood
of receiving any initial treatment, whereas lung function and
mMRC score were weaker predictors.
In our study, relatively few patients received LABAs or LAMAs as
monotherapy. Although such treatments are now recommended
as ﬁrst-line options for many patients,9,12 only LABA monotherapy
would have been available in the earliest cohorts because the ﬁrst
LAMA was licensed in the UK in 2002.22 Monotherapy as ﬁrst-line
treatment increased in the later cohorts but remained low
Table 1. Patient baseline characteristics and demographics (overall
population)
Characteristics N=20,154
Age, years, median (IQR) 66 (59–73)
Gender, male, n (%) 10,509 (52)
Body mass index, kg/m2, median (IQR) 26.5 (23–30)
Smoking status, n (%)
Non-smoker 893 (4.4)
Smoker 9,304 (46)
Ex-smoker 9,954 (49)
Comorbid asthma (at any time), n (%) 4,056 (20)
Exacerbation rate during the year before and including the initial date of
COPD diagnosis, n (%)
0 12,147 (60)
1 4,819 (24)
2 1,700 (8.4)
⩾ 3 1,488 (7.4)
Lung function, n (%)
Grade 1 (mild: FEV1 ⩾ 80% predicted) 3,012 (15)
Grade 2 (moderate: 50% ⩽ FEV1o80% predicted) 11,077 (55)
Grade 3 (severe: 30%⩽ FEV1o50% predicted) 5,090 (25)
Grade 4 (very severe: FEV1o30% predicted) 975 (4.8)
mMRC score, n (%)
Unknown 3,969 (20)
0–1 9,371 (46)
2+ 6,814 (34)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; IQR, interquartile range; mMRC, modiﬁed Medical
Research Council.
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compared with the use of LABA+ICS. The use of ICS monotherapy
decreased over time; however, 13% of patients were still
prescribed such treatment in the 2007–2010 cohort. The
prescribing of ICS-containing regimens remained similar between
1997 and 2001, and 2007 and 2010, with an increased use of ICS
combination therapies compensating for the reduction in the use
of ICS monotherapy.
There were notable differences in the treatment predictors
identiﬁed in the total study population (patients treated up to
1 year before diagnosis) and the subgroup that received their ﬁrst
treatment at diagnosis. Comorbid asthma was a predictor of initial
maintenance treatment before diagnosis, but not at diagnosis.
One explanation could be that comorbid asthma, whether
correctly or incorrectly diagnosed, drives maintenance treatment
decisions before a formal COPD diagnosis, but once COPD is
diagnosed in its own right it drives treatment decisions by itself.
Furthermore, mMRC score was predictive of treatment before
diagnosis but not at diagnosis. One explanation could be that the
GOLD strategy at the time recommended treatment based on
lung function and not on symptoms.11 At diagnosis, lung function
would, therefore, have been the main consideration when
determining therapy.
Interpretation of ﬁndings in relation to previously published work
Consistent with previous studies,13,17,26–28 our study showed high
prescribing rates of ICS/LABA in patients with COPD. Similarly,
a disconnect between real-world prescription patterns and
national guidelines or GOLD treatment recommendations has
been documented in other countries.18,19,21,28,29 The novelty of
our study compared with these earlier descriptive studies was in
analysing the drivers of treatment decisions in primary care.
Strengths and limitations of the study
This was a large study of real-life data, highlighting differences
between COPD guidelines and real-world prescribing patterns in
the UK. The length of the study and its historical nature give a
unique insight into prescribing patterns and drivers of primary
care treatment decisions before, during and after the introduction
of major UK and international guidelines that are still in
place today.
Potential study limitations include the fact that the data set
reﬂects UK opinions, attitudes and drug availability, and analyses
in other countries are needed before these ﬁndings can be
extrapolated more widely. Although the gap between real-world
prescription patterns and guidelines is evident in our ﬁndings,
Figure 1. Initial pharmacological therapy (overall population). ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist.
Figure 2. Initial pharmacological therapy according to year of COPD diagnosis. ICS, inhaled corticosteroid; LABA, long-acting β2-agonist;
LAMA, long-acting muscarinic antagonist.
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factors contributing to this and the strength of their correlation
need to be substantiated. Another limitation is that data recording
in this study may have been incomplete. For example, prescrip-
tions or exacerbations during Emergency Department visits may
have not been recorded properly; in earlier cohorts, an initial
asthma diagnosis may have later changed into one of COPD
without the asthma code being terminated, and prescriptions in
the earlier cohorts would have been handwritten and may have
been lost or damaged.
A further limitation is that some patients who appeared to have
received unnecessary ICS prescriptions may have had comorbid
asthma that was not recorded (between 2004 and 2006, the QOF
deﬁnitions prevented patients from being in both the asthma and
COPD registers; patients with COPD and comorbid asthma would,
therefore, have been missed).30 Thus, these results should be
interpreted with caution. Notably, the 2014 GOLD and Global
Initiative for Asthma Global Strategy for Asthma Management and
Prevention reports now highlight asthma-COPD overlap syndrome
as an important factor to consider in managing patients with
COPD.12,31
This study also compares prescribing patterns from an era that
predates the GOLD A-D classiﬁcation. Data reported by GOLD A-D
here are, therefore, illustrative of habits, but they were not part of
the framework used by physicians at that time.
Finally, this study only considers data from primary care
practice, and any therapies prescribed by pulmonologists will
not have been included. This might explain some of the patients
who did not have any recorded prescription in this study (28% in
Table 2. Factors predictive of any initial therapy: multivariable analysis
(reduced best-ﬁtting model)
Patients (n) Odds of being prescribed any initial therapy
versus no therapy
ORa (95% CI) P value Overall P valueb
All patients, including those treated at or up to 1 year before COPD
diagnosisc
Comorbid asthma diagnosis (reference category: no; (n= 12,922))
Yes 3,263 3.88 (3.43, 4.40) o0.001 o0.001
Lung function grade (reference category: 2; (n= 8,964))
1 2,274 0.87 (0.78, 0.97) 0.009 0.001
3 4,163 1.10 (1.01, 1.20) 0.038
4 784 1.13 (0.95, 1.36) 0.174
mMRC score (reference category: 0; (n= 2,234))
1 7,137 1.17 (1.05, 1.31) 0.005 o0.001
2 4,003 1.22 (1.08, 1.38) 0.001
3 2,232 1.26 (1.10, 1.46) 0.001
4 579 1.40 (1.12, 1.75) 0.003
Annual exacerbation rate (reference category: 0; (n= 9,708))
1 3,857 2.33 (2.12, 2.56) o0.001 o0.001
2 1,405 3.60 (3.03, 4.27) o0.001
⩾ 3 1,215 4.62 (3.75, 5.69) o0.001
Subgroup of patients, excluding those treated before COPD diagnosisd
Comorbid asthma diagnosis (reference category: no; (n= 7,229))
Yes 550 0.80 (0.65, 0.98) 0.028 0.028
Lung function grade (reference category: 2; (n= 4,336))
1 1,201 0.79 (0.68, 0.92) 0.002 0.007
3 1,870 1.01 (0.90, 1.14) 0.835
4 372 1.13 (0.89, 1.44) 0.303
Annual exacerbation rate (reference category: 0; (n= 5,827))
1 1,432 1.74 (1.54, 1.97) o0.001 o0.001
2 338 1.78 (1.41, 2.23) o0.001
⩾ 3 182 1.34 (0.97, 1.84) 0.072
mMRC score (reference category: 0; (n= 921))e
1 2,671 — — NS
2 1,506 — —
3 796 — —
4 202 — —
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 s; mMRC, modiﬁed
Medical Research Council; NS, not signiﬁcant; OR, odds ratio.
Lung function grades are deﬁned as follows: (1) ⩾ 80% predicted; (2) 50%
⩽ FEV1o80% predicted; (3) 30% ⩽ FEV1o50% predicted; (4) FEV1o30%
predicted.12
aAdjusted for body mass index and gender.
bΧ2 test.
cAnalysis in the subset of 16,185 (80%) patients with mMRC data available.
dAnalysis in the full subgroup of patients (n= 7,779), including patients
with missing mMRC data.
eVariable was not included in the multivariable model, and thus OR could
not be obtained.
Table 3. Factors predictive of initial maintenance therapy prescription
(long-acting agents; ICS with/without long-acting agents;
theophylline): multivariable analysis (reduced best-ﬁtting model)
Patients (n) Odds of being prescribed initial maintenance
therapy versus short-acting or no therapy at all
ORa (95% CI) P value Overall P valueb
All patients, including those treated at or up to 1 year before COPD
diagnosisc
Comorbid asthma diagnosis (reference category: no; (n= 12,922))
Yes 3,263 5.47 (4.97, 6.02) o0.001 o0.001
Lung function grade (reference category: 2; (n= 8,964))
1 2,274 0.96 (0.87, 1.06) 0.434 o0.001
3 4,163 1.18 (1.09, 1.28) o0.001
4 784 1.39 (1.18, 1.63) o0.001
mMRC score (reference category: 0; (n= 2,234))
1 7,137 1.17 (1.06, 1.30) 0.003 o0.001
2 4,003 1.29 (1.15, 1.44) o0.001
3 2,232 1.31 (1.15, 1.49) o0.001
4 579 1.67 (1.37, 2.04) o0.001
Annual exacerbation rate (reference category: 0; (n= 9,708))
1 3,857 1.62 (1.49, 1.75) o0.001 o0.001
2 1,405 2.54 (2.24, 2.87) o0.001
⩾ 3 1,215 3.78 (3.27, 4.38) o0.001
Subgroup of patients, excluding those treated before COPD diagnosisd
Lung function grade (reference category: 2; (n= 4,336))
1 1,201 0.88 (0.70, 1.10) 0.255 0.001
3 1,870 1.22 (1.03, 1.46) 0.023
4 372 1.63 (1.20, 2.21) 0.002
Annual exacerbation rate (reference category: 0; (n= 5,827))
1 1,432 1.50 (1.26, 1.79) o0.001 o0.001
2 338 1.80 (1.32, 2.45) o0.001
⩾ 3 182 1.30 (0.82, 2.07) 0.264
Comorbid asthma diagnosis (reference category: no; (n= 7,229))e
Yes 550 — — NS
mMRC score (reference category: 0; (n= 921))e
1 2,671 — — NS
2 1,506 — —
3 796 — —
4 202 — —
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled
corticosteroid; mMRC, modiﬁed Medical Research Council; NS, not
signiﬁcant; OR, odds ratio.
Lung function grades are deﬁned as follows: (1) ⩾ 80% predicted; (2) 50%
⩽ FEV1o80% predicted; (3) 30% ⩽ FEV1o50% predicted; (4) FEV1o30%
predicted.12
aAdjusted for body mass index and gender.
bΧ2 test.
cAnalysis in the subset of 16,185 (80%) patients with mMRC data available.
dAnalysis in the full subgroup of patients (n= 7,779), including patients
with missing mMRC data.
eVariable was not included in the multivariable model, and thus OR could
not be obtained.
COPD prescribing decisions in UK primary care
K Gruffydd-Jones et al
4
npj Primary Care Respiratory Medicine (2016) 16002 © 2016 Primary Care Respiratory Society UK/Macmillan Publishers Limited
total). However, it should be noted that in the UK the vast majority
of prescriptions are written in primary care; prescriptions are
written by specialists only in emergencies. Therefore, the effect of
this on our results is expected to be minimal.
Implications for future research, policy and practice
The results from this study raise several interesting questions for
future research. One question that arises from this study is
whether or not any of the other comorbidities identiﬁed in
this population (e.g., cardiovascular disease; depression/anxiety;
diabetes) are predictors of doctors’ prescribing habits (such as
comorbid asthma has been shown to be). These analyses were
outside the remit of our study, but they would be important areas
to explore further in future research. Similarly, one could explore
the potential effect of socio-economic variables, such as
differences in educational level across the population, on
treatment choices. In addition, it would be valuable to further
characterise the large proportion of patients who had received no
treatment (28%).
Traditionally, COPD has been considered as more prevalent in
men than in women. However, evidence suggests that the
prevalence of COPD is increasing in women, even in populations
in which the overall prevalence may be decreasing.32 A recent
WHO report states that COPD now affects men and women almost
equally.33 Although our model was adjusted for gender, the effect
of gender on treatment choice would be an interesting research
topic to consider.
There is a pressing need to change healthcare professionals’
behaviour so they understand that adherence to COPD guidelines
has the potential to improve treatment outcomes for large
numbers of patients, by reducing inappropriate exposure to ICS
and its associated risks (e.g., pneumonia),34 as well as to reduce
the societal burden of the disease. The reasons why treatment and
prescriptions do not comply with guideline recommendations
remain unclear and were outside the remit of this study. More
research is needed to elucidate this further; however, one likely
possibility is that physicians simply react to the patients in front of
them, and their treatment decisions may be guided more by
clinical events rather than by guideline recommendations. Indeed,
GOLD now recognises clinical events, such as exacerbations, to be
as important as lung function when making decisions on initial
therapy.12 However, the need to treat any patient with symptoms
or exacerbations is clear. Non-compliance with guidelines may
also be related to failure to make a diagnosis or to treat according
to a diagnosis, or insufﬁcient/inaccurate knowledge of the disease
process or the guidelines. Finally, it may be that the habit of
prescribing ICS starts with asthma (appropriately) and passes on to
prescriptions for COPD, despite differences in the licensed
indications for the two conditions. Although changing physicians’
prescribing habits is not an easy task, tools and support services
could be implemented to facilitate the correct use of guidelines.
Suggestions include more frequent audits, reviews (such as the
clinical support services provided by Optimum Patient Care35),
availability of prescribing advisors or templates in primary care
with feedback on management steps according to guidelines and
provision of more educational materials.
This study was conducted before approval of the LABA/LAMA
ﬁxed-dose combinations that are now available for the treatment
of COPD (once-daily indacaterol/glycopyrronium 110/50 μg and
vilanterol/umeclidinium 25/62.5 μg were approved in the EU and
the US, respectively, in 2013).36,37 Therefore, the use of these
therapies was close to zero throughout the study. These dual
bronchodilator treatments are now central to COPD management,
being an alternative treatment choice to LABA or LAMA
monotherapy in GOLD Group B patients (high-symptom burden;
low-exacerbation risk) and an alternative to LABA/ICS combination
therapy in GOLD Group C or D patients (severe airﬂow limitation,
or high risk of COPD exacerbations).12 It will be interesting to
investigate what effect the approval of these newer therapies will
have on COPD prescribing patterns in the coming years,
particularly in relation to the use of ICS/LABA combinations.
Conclusions
In the UK, many patients who received a diagnosis of COPD did
not receive any pharmacological treatment despite symptoms
and exacerbations. ICS-containing regimens were widely used
irrespective of exacerbations, and patients were prescribed ICS
monotherapy in the absence of comorbid asthma, which was not
recommended by any COPD guidelines. The percentage of
patients who did not receive treatment and the percentage of
patients prescribed ICS monotherapy decreased in the later
cohorts. The use of ICS combination therapies, including ICS
+LABA, ICS+LAMA and ICS+LABA+LAMA, all increased in the later
cohorts. Comorbid asthma, high exacerbation rate, increased
symptoms and poor lung function were identiﬁed as drivers of
prescription of initial and maintenance therapy.
MATERIALS AND METHODS
Data source
The Optimum Patient Care Research Database (OPCRD),38 which at the
time of data extraction comprised anonymised data from 318 UK practices,
was used.39 The OPCRD is a quality-controlled, longitudinal, primary care
respiratory database that combines routinely recorded clinical data from
electronic patient records with patient-reported data collected using
disease-speciﬁc questionnaires. The clinical data extracted from primary
care management systems include lung function data, patient demo-
graphics, diseases typically comorbid with COPD, exacerbation history,
mMRC score and therapy history.
The OPCRD has been approved by the Trent Multicentre Research Ethics
Committee for clinical research use. The independent Anonymized Data
Ethics Protocols and Transparency committee veriﬁed and approved the
planned analysis.39
This study is registered at www.clinicaltrials.gov (NCT01786720).
Patient population
The patients included were newly diagnosed with COPD, ⩾ 40 years of age
at the date of diagnosis, which was based on the QOF-approved Read
Code (Supplementary Methods), with spirometry data supportive of a
COPD diagnosis (post-bronchodilator FEV1/forced vital capacityo0.7)
recorded in the 5-year window around the date of diagnosis. The data
used in these analyses were from the years 1997 to 2013. To examine
changes in treatment patterns over time, patients were split into three
cohorts based on the date of diagnosis: (1) 1997–2001; (2) 2002–2006; and
(3) 2007–2010. Cohorts were chosen to assess the impact of the ﬁrst GOLD
report publication (2001), UK approval of tiotropium (2002) and introduc-
tion of the QOF (2004).22,24,40
COPD initial therapy was deﬁned as pharmacological therapy prescribed
during the year before and at the date of COPD diagnosis. There was no
minimum number of prescriptions required to mark the initiation of
pharmacological treatment. COPD therapies were grouped by treatment
class. To identify possible drivers of treatment choice, analyses were
conducted in subgroups according to year of diagnosis; the presence of
comorbid asthma (based on physician-recorded Read Codes for asthma);
lung function grade; mMRC dyspnoea scale score; and baseline
exacerbation rate (at or within 1 year before COPD diagnosis).
Clinical variables
Lung function grades and mMRC scores recorded closest to the date of
COPD diagnosis were used in this analysis. Lung function grade was
determined using GOLD Stage 1, 2, 3 and 4 criteria,12 and mMRC scores
were based on the 5-point scale of the British Medical Research Council
questionnaire assessing perceived breathlessness12 (see Supplementary
Information for further details).
Exacerbation rates were calculated during the year before and including
the date of COPD diagnosis. Data were obtained from medical records.
Exacerbations were deﬁned as any one or more of the following:
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(i) COPD-related hospital admissions or Emergency Department atten-
dance; (ii) the use of acute oral corticosteroids; and/or (iii) general
practitioner consultations for lower respiratory tract infections. Two
exacerbations occurring within 2 weeks of one another were counted
only once.
Statistical analysis
Summary statistics were generated for all baseline variables. COPD
therapies prescribed before and at the date of COPD diagnosis were
quantiﬁed as a complete data set. Factors signiﬁcantly (Po0.05) affecting
(i) the odds of being prescribed any initial COPD therapy versus no therapy
and (ii) the odds of receiving initial maintenance therapy versus short-
acting agents or no therapy were identiﬁed with univariable logistic
regression. These were included in a multivariable logistic regression
model with stepwise reduction to derive a best-ﬁtting model of non-
collinear (Spearman’s co-efﬁcient ⩽ 0.3) predictors. The models were
adjusted for body mass index and gender, as these variables were found to
be signiﬁcant predictors of treatment. Analyses were conducted within the
total population of patients receiving ﬁrst therapy (based on prescribing
during the year before and at the date of COPD diagnosis) and in the
subgroup of patients who received their ﬁrst therapy on the date of
COPD diagnosis. Potential predictors studied were as follows: year of
COPD diagnosis, comorbid asthma, lung function, mMRC score, annual
exacerbation rates and GOLD Group (B versus A, D versus C and C+D
versus A+B). Multivariable analyses for the total study population were
undertaken on the subset of patients with mMRC data available.
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